Results 91 to 100 of about 240,836 (199)

Journal of Cardiothoracic and Vascular Anesthesia / Intraoperative off-label reversal of apixaban by andexanet alfa while on VA-ECMO immediately after emergent surgery for acute type A aortic dissection

, 2021
The authors report a case of intraoperative reversal of apixaban with andexanet alfa in a patient supported with venoarterial extracorporeal membrane oxygenation due to low- cardiac-output immediately after surgery for acute type A aortic dissection and ...
Kainz, Matthias, Schellongowski, Peter, Bsuchner, Paul, Dworschak, Martin   +3 more
core   +1 more source

POSSIBILITIES OF INHIBITING ANTICOAGULANT ACTIVITIES THAT INHIBIT XA-FACTOR

Атеротромбоз, 2019
The article deals with the possibility of suppressing the effect of drugs inhibiting the activity of the Xa-Factor of the clotting blood system. Wide indications for oral anticoagulants are atrial fibrillation, venous thrombosis, thromboembolism, etc ...
A. D. Erlich
doaj   +1 more source

Efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐associated intracranial haemorrhages

Internal Medicine Journal, Volume 55, Issue 7, Page 1114-1119, July 2025.
Abstract Background An increasing number of patients in Australia are taking direct oral anticoagulants for a variety of indications since their introduction in the treatment landscape. There has always been some concern about the optimal management approach in the setting of major and/or life‐threatening bleeding.
Sara Shu‐Ling Ng, Hashim Noori, Diem Nguyen, Zhengbang Wang, Danny Hsu   +4 more
wiley   +1 more source

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. [PDF]

, 2016
Background Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers.
Eikelboom, John W, Gibson, C. Michael, Lu, Genmin, ANNEXA-4 Investigators, Lopez-Sendon, Jose, Cohen, Alexander T, Wiens, Brian L., Siegal, Deborah M, Connolly, Stuart J., Beyer-Westendorf, Jan, Crowther, Mark, Wiens, Brian L, Meeks, Brandi, Lim, W. Ting, Gibson, C Michael, Leeds, Janet, Cohen, Alexander T., Nakamya, Juliet, Connolly, Stuart J, Lim, W Ting, Conley, Pamela B., Gold, Alex, Curnutte, John T, Siegal, Deborah M., Middeldorp, Saskia, Goodman, Shelly, Verschuren, Franck, Milling, Truman J, Milling, Jr, Verhamme, Peter, Conley, Pamela B, Schmidt, Jeannot, Bronson, Michele D, Curnutte, John T., Bronson, Michele D., Zotova, Elena, Albaladejo, Pierre, Eikelboom, John W.   +37 more
core   +1 more source

sj-docx-1-cat-10.1177_10760296221110568 - Supplemental material for Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

, 2022
Supplemental material, sj-docx-1-cat-10.1177_10760296221110568 for Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds by Alex C ...
Bríain Ó Hartaigh (13013324), Zhun Cao (13013327), Alex C. Spyropoulos (5093291), Michaela Petrini (13013333), Harjeet Caberwal (13013330), Cheng Wang (102692), Craig Lipkin (8429892)   +6 more
core   +1 more source

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. [PDF]

J Pharm Pract
Medication-use evaluations are meant to ensure that medication-use processes are consistent with prevailing standards of care, assure optimal use of therapy, and reduce the risk of medication-related problems.
Fera T, Burnett A, Grandoni J, Moore MR, Nussbaum BB, Pollack CV, Rose AE, Spinler SA, Streiff MB, Turck CJ, Fanikos J.   +10 more
europepmc   +2 more sources

The Efficacy of Andexanet Alfa for the Reversal of Factor Xa Inhibitors Is Not Influenced by Hemodilution with Different Volume Expanders. [PDF]

J Clin Med
Background: Andexanet alfa is a specific antidote for factor Xa (FXa) inhibitors. It is licensed to treat patients under FXa inhibitor therapy with life-threatening bleeding.
Wienhold J, Rossaint R, Vandeput E, Grottke O.   +3 more
europepmc   +2 more sources

Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients

, 2021
Specific antagonists have been developed for the reversal of direct oral anticoagulants (DOAC). We investigated the impact of these reversal agents on the plasma concentration and visco-elastic test results of dabigatran and factor Xa inhibitors.
Daniel Oberladstätter, Marcin F. Osuchowski, Herbert Schöchl, Grottke, Oliver, Christoph J. Schlimp, Oberladstätter, Daniel, Schlimp, Christoph J., Wolfgang Voelckel, Schöchl, Herbert, Voelckel, Wolfgang, Zipperle, Johannes, Osuchowski, Marcin F., Johannes Zipperle, Oliver Grottke   +13 more
core   +1 more source

Correction to: Andexanet Alfa: First Global Approval [PDF]

Drugs, 2018
The article Andexanet Alfa: First Global Approval, written by Young-A Heo, was originally published Online First without open access.
openaire   +2 more sources

Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding

Nature Communications
Direct oral anticoagulants (DOACs) targeting activated factor Xa (FXa) are used to prevent or treat thromboembolic disorders. DOACs reversibly bind to FXa and inhibit its enzymatic activity.
Wojciech Jankowski, Stepan S. Surov, Nancy E. Hernandez, Atul Rawal, Marcos Battistel, Daron Freedberg, Mikhail V. Ovanesov, Zuben E. Sauna   +7 more
doaj   +1 more source